NCT03473314View on ClinicalTrials.gov

Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

July 11, 2020

Study Completion Date

July 21, 2020

Conditions
Non-Tuberculous Mycobacterial Pneumonia
Interventions
DRUG

Nitric Oxide gas at 160ppm

Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.

Trial Locations (1)

V5Z-1L8

Gordon Leslie Diamond Health Care Centre, Vancouver

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

University of British Columbia

OTHER

NCT03473314 - Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection | Biotech Hunter | Biotech Hunter